{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:14:05Z","timestamp":1758816845067},"reference-count":30,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Abstract missing (Short communication)<\/jats:p>","DOI":"10.2340\/actadv.v104.41984","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T13:42:27Z","timestamp":1728567747000},"page":"adv40984","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Improvement of Bullous Pemphigoid with Hyperkeratosis and Palmoplantar Keratoderma in Two Patients Treated with Dupilumab"],"prefix":"10.2340","volume":"104","author":[{"given":"Giulia","family":"Pascolini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feliciana","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Pira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biagio","family":"Didona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Di Zenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"77987","doi-asserted-by":"crossref","unstructured":"Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 1: clinical manifestations. J Dtsch Dermatol Ges 2011; 9: 844-856.","DOI":"10.1111\/j.1610-0387.2011.07793.x"},{"key":"77988","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1610-0387.2011.07793.x","DOI":"10.1111\/j.1610-0387.2011.07793.x"},{"key":"77989","doi-asserted-by":"crossref","unstructured":"Fania L, Didona D, Pacifico V, Mariotti F, De Luca N, Abeni D, et al. Bullous pemphigoid with hyperkeratosis and palmoplantar keratoderma: three cases. J Dermatol 2018; 45: 1135-1140.","DOI":"10.1111\/1346-8138.14529"},{"key":"77990","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/1346-8138.14529","DOI":"10.1111\/1346-8138.14529"},{"key":"77991","doi-asserted-by":"crossref","unstructured":"Borradori L, Van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2022; 36:1689-1704.","DOI":"10.1111\/jdv.18220"},{"key":"77992","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.18220","DOI":"10.1111\/jdv.18220"},{"key":"77993","doi-asserted-by":"crossref","unstructured":"Zhao L, Wang Q, Liang G, Zhou Y, Yiu N, Yang B, et al. Evaluation of dupilumab in patients with bullous pemphigoid. JAMA Dermatol 2023; 159: 953-960.","DOI":"10.1001\/jamadermatol.2023.2428"},{"key":"77994","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.2428","DOI":"10.1001\/jamadermatol.2023.2428"},{"key":"77995","doi-asserted-by":"crossref","unstructured":"Cao P, Xu W, Zhang L. Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review. Front Immunol 2022; 13: 928621.","DOI":"10.3389\/fimmu.2022.928621"},{"key":"77996","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fimmu.2022.928621","DOI":"10.3389\/fimmu.2022.928621"},{"key":"77997","doi-asserted-by":"crossref","unstructured":"Huang D, Zhang Y, Yu Y, Jiang Y, Kong L, Ding Y, et al. Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: a prospective cohort study. Int Immunopharmacol 2023; 125: 111157.","DOI":"10.1016\/j.intimp.2023.111157"},{"key":"77998","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111157","DOI":"10.1016\/j.intimp.2023.111157"},{"key":"77999","doi-asserted-by":"crossref","unstructured":"Miller AC, Temiz LA, Adjei S, Duran MA, Sassmannshausen J, Dominguez A, et al. Treatment of bullous pemphigoid with dupilumab: a case series of 30 patients. J Drugs Dermatol 2024; 23: e144-e148.","DOI":"10.36849\/JDD.8258"},{"key":"78000","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.36849\/JDD.8258","DOI":"10.36849\/JDD.8258"},{"key":"78001","doi-asserted-by":"crossref","unstructured":"Hamada T, Tsuruta D, Fukuda S, Ishii N, Teye K, Numata s, et al. How do keratinizing disorders and blistering disorders overlap? Exp Dermatol 2013; 22: 83-87.","DOI":"10.1111\/exd.12021"},{"key":"78002","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/exd.12021","DOI":"10.1111\/exd.12021"},{"key":"78003","doi-asserted-by":"crossref","unstructured":"Razack EM, Premalatha S, Rao NR, Zahra A. Acanthosis palmaris in a patient with bullous pemphigoid. J Am Acad Dermatol 1987; 16: 217-219.","DOI":"10.1016\/S0190-9622(87)80066-X"},{"key":"78004","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0190-9622(87)80066-X","DOI":"10.1016\/S0190-9622(87)80066-X"},{"key":"78005","doi-asserted-by":"crossref","unstructured":"Bolling MC, Mekkes JR, Goldschmidt WF, Van Noesel CJM, Jonkman MF, Pas HH, et al. Acquired palmoplantar keratoderma and immunobullous disease associated with antibodies to desmocollin 3. Br J Dermatol 2007; 157: 168-173.","DOI":"10.1111\/j.1365-2133.2007.07920.x"},{"key":"78006","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2007.07920.x","DOI":"10.1111\/j.1365-2133.2007.07920.x"},{"key":"78007","doi-asserted-by":"crossref","unstructured":"Mi Z, Sun F, Wang Z, Zhao Q, Pan F, Yan X, et al. Severe atopic eczema treated by dupilumab in a child with keratitis-ichthyosis-deafness syndrome. Australas J Dermatol 2022; 63: 527-529.","DOI":"10.1111\/ajd.13913"},{"key":"78008","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ajd.13913","DOI":"10.1111\/ajd.13913"},{"key":"78009","doi-asserted-by":"crossref","unstructured":"Yan S, Wu X, Jiang J, Yu S, Fang X, Yang H, et al. Dupilumab improves clinical symptoms in children with Netherton syndrome by suppressing Th2-mediated inflammation. Front Immunol 2022; 13: 1054422.","DOI":"10.3389\/fimmu.2022.1054422"},{"key":"78010","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fimmu.2022.1054422","DOI":"10.3389\/fimmu.2022.1054422"},{"key":"78011","doi-asserted-by":"crossref","unstructured":"Odorici G, Schenetti C, Marzola E, Monti A, Borghi A, Corazza M. Treatment of Netherton syndrome with dupilumab. J Dtsch Dermatol Ges 2022; 20: 1636-1640.","DOI":"10.1111\/ddg.14914"},{"key":"78012","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ddg.14914","DOI":"10.1111\/ddg.14914"},{"key":"78013","doi-asserted-by":"crossref","unstructured":"Wu PC, Dai YX, Li CL, Chen CC, Chang YT, Ma SH. Dupilumab in the treatment of genodermatosis: a systematic review. J Dtsch Dermatol Ges 2023; 21: 7-17.","DOI":"10.1111\/ddg.14924"},{"key":"78014","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ddg.14924","DOI":"10.1111\/ddg.14924"},{"key":"78015","doi-asserted-by":"crossref","unstructured":"Galdo G, Fania L. A Netherton syndrome case report: response to dupilumab treatment. Dermatol Ther 2022; 35: e15862.","DOI":"10.1111\/dth.15862"},{"key":"78016","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.15862","DOI":"10.1111\/dth.15862"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/41984\/47931","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/41984\/47931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T13:42:49Z","timestamp":1728567769000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/41984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":30,"URL":"https:\/\/doi.org\/10.2340\/actadv.v104.41984","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,10]]}}}